Localized HR-Positive Breast Cancer — Year in Review Series on Relevant New Datasets and Advances

Featuring perspectives from Dr Harold J Burstein and Dr Joyce O’Shaughnessy, including the following topics:

Introduction: ODAC — April 30, 2026 (00:00)
Adjuvant CDK4/6 Inhibitors (13:03)
Adjuvant Oral Selective Estrogen Receptor Degraders (21:53)
Premenopausal Patients (30:52)
Duration of Adjuvant Endocrine Treatment (38:44)
Genomic Predictors of Chemotherapy Benefit (47:19)
Neoadjuvant Treatment (55:13)